❤️ Heart & Vascular peptides

The eight-amino-acid effector hormone of the renin-angiotensin system, marketed as Giapreza, an intravenous vasopressor approved in 2017 to raise blood pressure in adults with septic or other distributive shock that resists conventional vasopressors.

A synthetic 20-residue hirudin-derived direct thrombin inhibitor (Hirulog) that reversibly blocks both the active site and exosite I of thrombin; FDA-approved as Angiomax (2000) for intravenous anticoagulation during percutaneous coronary intervention.

A 65-amino-acid recombinant hirudin (desulfato-hirudin) and subcutaneous direct thrombin inhibitor approved by the FDA as Iprivask in 2003 for deep-vein thrombosis prophylaxis after hip replacement; the product was later discontinued in the United States.

A synthetic V2-selective analog of vasopressin, FDA approved since 1978, that concentrates urine through renal aquaporin-2 trafficking and raises von Willebrand factor and factor VIII without the pressor activity of the parent hormone.

A once-weekly GLP-1 receptor agonist built as a GLP-1 analog fused to a modified IgG4 Fc domain, approved since 2014 for type 2 diabetes and since 2020 for cardiovascular risk reduction, but never for weight management.

A 60-amino-acid recombinant plasma kallikrein inhibitor engineered by phage display from a Kunitz domain of tissue factor pathway inhibitor, FDA approved since 2009 as Kalbitor for acute hereditary angioedema attacks, carrying a boxed anaphylaxis warning.

Merck's MK-0616, an oral macrocyclic peptide that blocks PCSK9 binding to the LDL receptor, approved by the FDA on July 15, 2026 as Lipfendra for LDL-cholesterol lowering after the CORALreef phase 3 trials showed roughly 56 to 60% placebo-adjusted reductions.

A synthetic cyclic heptapeptide glycoprotein IIb/IIIa antagonist modeled on the KGD motif of barbourin, a pygmy rattlesnake venom disintegrin; FDA-approved as Integrilin (1998) for intravenous antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.

A synthetic decapeptide bradykinin B2 receptor antagonist, FDA approved since 2011 (generics since 2019) as a self-administered subcutaneous injection for acute attacks of hereditary angioedema in adults, that failed in ACE-inhibitor angioedema and COVID-19 trials.

A synthetic 14-residue cyclic peptide CXCR4 antagonist, FDA approved since 2023 as Aphexda, given with filgrastim to mobilize hematopoietic stem cells into the blood for collection before autologous transplant in multiple myeloma.

A PEGylated dimer of two cyclic 15-amino-acid compstatin-family peptides that binds complement C3, FDA approved as a subcutaneous infusion for paroxysmal nocturnal hemoglobinuria (2021) and C3 glomerulopathy / primary IC-MPGN (2025) and as an intravitreal injection for geographic atrophy (2023).

A synthetic, lipidated hepcidin-mimetic peptide that blocks the iron exporter ferroportin, developed by Protagonist Therapeutics as PTG-300 and approved by the FDA in August 2026 as Mimrylo (Takeda) for erythrocytosis in adults with polycythemia vera.

Activin receptor type IIA-Fc fusion protein approved by the FDA on March 26, 2024 as Winrevair (sotatercept-csrk) for pulmonary arterial hypertension, with later label updates from the ZENITH and HYPERION outcome trials.

Elamipretide, a cardiolipin-binding mitochondrial tetrapeptide developed as SS-31, granted FDA accelerated approval in September 2025 as Forzinity for Barth syndrome after failed trials in mitochondrial myopathy and heart failure, and sold widely as a research peptide.

A synthetic twelve-residue vasopressin analog and prodrug of lysine-vasopressin that constricts splanchnic vessels through V1 receptors, used for decades in Europe for variceal bleeding and FDA approved since September 2022 for hepatorenal syndrome.

A cyclic nonapeptide hormone, also called antidiuretic hormone, that controls renal water reabsorption and vascular tone through V1a, V1b, and V2 receptors and is FDA approved as an intravenous vasopressor.

A recombinant activin receptor type IIB-Fc fusion protein that traps myostatin and related TGF-beta ligands to increase muscle mass; its clinical program went on hold in 2011 after vascular adverse events and the sponsor discontinued development in 2013.

A native 52-amino-acid vasodilator peptide of the calcitonin family, isolated from human pheochromocytoma in 1993 and tested by Japanese investigators as an intravenous infusion for ulcerative colitis, Crohn's disease, stroke and COVID-19 pneumonia without any approved product.

An endogenous seven-amino-acid peptide of the renin-angiotensin system that activates the MAS receptor and counteracts angiotensin II, developed clinically as TXA127 and tested for two decades across oncology, COVID-19, and muscle-wasting indications without an approval anywhere or a replicated efficacy result.

An endogenous peptide ligand for the APJ receptor with cardiovascular and metabolic research relevance.

Recombinant human alpha-atrial natriuretic peptide of 28 amino acids, approved in Japan in 1995 as Hanp for acute heart failure, where it is widely infused as a vasodilator and diuretic without a demonstrated mortality benefit.

A 37-amino-acid sensory neuropeptide and one of the most potent vasodilators described in humans; every FDA-approved drug in this space blocks CGRP rather than supplying it, and the peptide itself has no approved product.

A once-weekly GLP-1 receptor agonist made of a single-residue-modified exendin-4 peptide chemically conjugated to a human IgG4 Fc fragment, developed by Hanmi, licensed to and returned by Sanofi, and approved in South Korea for obesity in October 2026 with no US program.

A 155-amino-acid human growth factor that activates every FGF receptor in a heparin-dependent manner, studied in angiogenesis, wound-healing, and nerve-repair trials that never reached approval and sold almost exclusively as a laboratory reagent.

A synthetic 12-amino-acid TREM-1 inhibitor peptide derived from TREM-like transcript-1, infused intravenously in septic shock and COVID-19 trials, that did not meet its phase 2b primary endpoint and passed to Genfit in 2026 for a planned liver-failure trial.

Recombinant human B-type natriuretic peptide (32 amino acids), approved as Natrecor on August 10, 2001 for acutely decompensated heart failure; after ASCEND-HF found no outcome benefit, the US product was discontinued and the application's approval was withdrawn on June 15, 2020.

A two-chain peptide hormone of the insulin superfamily that signals through the RXFP1 receptor to produce vasodilation and antifibrotic effects, and whose recombinant form, serelaxin, failed the RELAX-AHF-2 phase 3 trial in acute heart failure.

An endogenous 11-amino-acid tachykinin encoded by the TAC1 gene that activates the neurokinin-1 receptor in pain, vasodilation and neuroimmune signaling, with no approved product anywhere and only small human provocation studies.

The acetylated N-terminal tetrapeptide of thymosin beta-4, degraded almost exclusively by ACE and studied in animals as an antifibrotic and anti-inflammatory signal, with the only human studies of the administered peptide run in the 1990s as a chemotherapy myeloprotectant.

A synthetic tetrapeptide (Ala-Glu-Asp-Arg) from the Khavinson bioregulator family, studied for cardiovascular tissue bioregulation and cardiac geroprotection.

A TGF-beta superfamily protein almost identical to myostatin in its signaling domain, famous for parabiosis-era rejuvenation claims that later work either failed to reproduce or traced to antibody cross-reactivity.

A synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator family, studied for vascular endothelial bioregulation and cardiovascular geroprotection.